Dan Hargrove, JD, LLM – PRESIDENT AND CHIEF EXECUTIVE OFFICER
A widely respected healthcare entrepreneur and attorney. Co-founder and Chief Development Officer at Cancer Insight. Program Director of the Cancer Vaccine Development Program (CVDP). Hargrove is a recognized expert on healthcare law, government contracts, the US FDA regulatory pathway, and clinical studies in oncology.
Randy Goldsmith, PhD – FOUNDER AND DIRECTOR
Formerly President and chief executive officer of The Texas Technology Development Center. Serial entrepreneur. Fund-manager of the McDermott Pre-Seed Fund; the Oklahoma Technology Business Finance Program, Emerging Ventures of Oklahoma Fund, Mississippi Technology Alliance Seed Fund. Randy is an internationally recognized leader in business incubation and emerging technology venture development.
Mark Horsey, MBA – CHIEF FINANCIAL OFFICER, SECRETARY AND TREASURER
Formerly Finance Director for Genzyme’s Multiple Sclerosis and Oncology Business Units, and Controller for Dell Computer Company’s $14B North American Consumer Business Unit. More than 17 years of broad international and domestic experience building financial and operational infrastructure for multi-national corporations in the biotech, information technology, and retail fields. Extensive knowledge of start-up finance and operational strategy.
George Peoples, MD – CHIEF MEDICAL OFFICER
Founder and Director of the Cancer Vaccine Development Program (CVDP), associated with the Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD. Current CEO of Cancer Insight and Professor of Surgery at USUHS and Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). Past Chair of the Cancer Program, San Antonio Military Medical Center and the past Deputy Director of the United States Military Cancer Institute. Has over 300 peer-reviewed manuscripts, abstracts, and book chapters on cancer, immune therapy and similar subjects.
Leon W. LeVan, PhD – CHEMISTRY MANUFACTURING AND CONTROLS
Leon has over 25 years of pharmaceutical development experience in chemistry, manufacturing, and controls (“CMC”) and in drug metabolism. Former Director of Process Development at Genzyme Corporation supporting Genzyme’s oncology products. Previous positions at Bone Care International, Inc. (acquired by Genzyme) and Hazleton Laboratories (now Covance). Participated in the preparation of two successful NDAs and several sNDAs and INDs.
Ian Thompson Jr., MD – PRINCIPLE INVESTIGATOR PROSTATE CANCER TRIALS
Director of the University of Texas Health Science Center at San Antonio’s Cancer Therapy & Research Center and a urologic oncologist who specializes in prevention, early detection, and treatment of prostate and other urologic cancers, including cancers of the kidney, bladder and testis. A trustee of the American Board of Urology, chairman of the Early Detection Research Network of the National Cancer Institute, and chair of the Genitourinary Cancer Committee of the Southwest Oncology Group, one of the largest cancer treatment trials organizations in the world.
Robert Svatek, MD – PRINCIPLE INVESTIGATOR BLADDER CANCER TRIALS
Professor at UTHSCSA Medical School; Doctorial of Medicine degree at University of Texas Medical Branch at Galveston, Texas with Highest Honors; Clinical Fellowship and Research in Urologic Oncology at University of Texas MD Anderson Cancer Center; Master of Science (MS) in Clinical Research Investigation at the University of Texas Health Science Center at Houston, Center for Clinical Research and Evidence-Based Medicine. Professional interest in identifying and testing novel therapies for patients with bladder cancer, and in improving the quality of surgical care for patients undergoing major surgery for invasive bladder cancer.
Charles Cantrell J.D., B.S.N. – DIRECTOR OF MEDICAL AFFAIRS
Charles has twenty-five years of broad clinical experience from the operating room, ICU, and burn wound care. Previous management experience at level 1 trauma operating room in San Antonio, and U.S. Army Burn Unit as a nurse in the ICU. Law degree from St. Mary’s Law School.
Will Quirk, JD – INTELLECTUAL PROPERTY AND REGULATORY AFFAIRS
Will is a partner and the head of the Intellectual Property Group at Rosenthal Pauerstein Sandoloski Agather LLP, Attorneys at Law. Prior to joining Rosenthal Pauerstein, Mr. Quirk worked at Kinetic Concepts where he served as Associate General Counsel, Chief I.P. Counsel and Director, Regulatory Affairs.